Fortress Biotech, Inc.
FBIO
$2.76
$0.072.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.43% | 14.23% | |||
| Total Other Revenue | -56.84% | -- | |||
| Total Revenue | 7.42% | 24.92% | |||
| Cost of Revenue | -54.36% | 49.69% | |||
| Gross Profit | 248.51% | -24.10% | |||
| SG&A Expenses | -55.07% | 51.02% | |||
| Depreciation & Amortization | 0.00% | -0.09% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -53.78% | 49.16% | |||
| Operating Income | 81.33% | -63.43% | |||
| Income Before Tax | 175.97% | 52.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 175.74% | 52.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -110.97% | 92.39% | |||
| Net Income | -62.22% | 246.32% | |||
| EBIT | 81.33% | -63.43% | |||
| EBITDA | 83.99% | -67.17% | |||
| EPS Basic | -72.85% | 203.35% | |||
| Normalized Basic EPS | 307.04% | 315.57% | |||
| EPS Diluted | -75.56% | 193.61% | |||
| Normalized Diluted EPS | 271.94% | 294.21% | |||
| Average Basic Shares Outstanding | 1.36% | 1.62% | |||
| Average Diluted Shares Outstanding | 10.99% | 12.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||